NCT06528392View on ClinicalTrials.gov

Efgartigimod for Stiff Person Syndrome (ESPS)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Stiff-Person Syndrome
Interventions
BIOLOGICAL

Efgartigimod

Efgartigiomd-hyaluroidase (EFG) is a neonatal Fc receptor (FcRn) inhibitor, which blocks the recycling of Immunoglobulin G (IgG), including pathogenic IgG

Trial Locations (1)

33612

University of South Florida, Carol and Frank Morsani Center for Advanced Healthcare, Tampa

All Listed Sponsors
lead

University of South Florida

OTHER